A new study showed that among outpatients with mild to moderate COVID-19, treatment with ivermectin, compared with placebo, did not significantly improve time to recovery in this trial that enrolled more than 1,500 participants in the United States.
A lack of treatment effect was also seen for secondary clinical outcomes including hospitalization, death, or acute care visits. These findings do not support the use of ivermectin in patients with mild to moderate COVID-19.
